Effect of the CCND1 A870G polymorphism on prostate cancer risk: A meta-analysis of 3,820 cases and 3,825 controls

Abstract

Background: Cyclin D1 (CCND1) is critical in the transition of the cell cycle from the G1 to S phases, and unbalanced cell cycle regulation is a hallmark of carcinogenesis. Numerous epidemiological studies have evaluated the association between the CCND1 A870G polymorphism and the risk of prostate cancer (PCa). However, these studies have yielded conflicting results. Methods: In the present study, the possible association above was assessed by a meta-analysis. Eligible articles were identified for the period up to July 2014. Pooled odds ratios (ORs) with 95% confidence intervals (95% CI) were appropriately derived from fixed effects or random effects models. Results: A total of ten case-control studies, which included 3,820 cases and 3,825 controls, were identified. Overall, the allelic/genotypic association between the G870A polymorphism and prostate cancer was nonsignificant (OR=1.045, 95% CI=0.947 to 1.153 for A versus G, P=0.380; OR=1.088, 95% CI=0.896 to 1.321 for AA versus GG, P=0.393; OR=1.044, 95% CI=0.941 to 1.158 for GA versus GG, P=0.414; OR=1.053, 95% CI=0.955 to 1.161 for the dominant model AA+GA versus GG, P=0.303; OR=1.072, 95% CI=0.881 to 1.306 for the recessive model AA versus AA+GA, P=0.486). Moreover, subgroup analyses according to ethnicity failed to demonstrate a significant association between this polymorphism and prostate cancer. In addition, we also performed a stratified analysis of cases with PCa metastasis, and the results supported the findings of no significant association between CCND1 A870G polymorphism and metastasis risk of PCa. Conclusions: Our results suggest that the CCND1 A870G polymorphism might not be a potential candidate for predicting prostate cancer risk, including metastasis risk.